Introduction
Tea is one of the most popular beverages consumed worldwide. Drinking tea, especially green tea, inhibits the growth of several tumors in animal models, including cancers of the skin, lung, esophagus, breast, stomach, small intestine, colon, liver, pancreas, and mammary glands, (1, 2) and is associated with a lower incidence of cancer in humans. (1, 3, 4) The components of green tea responsible for these effects are catechins, which are polyphenols with potent antioxidant capacity that have been shown to inhibit mutation, tumor cell growth, tumor initiation, tumor progression, and the activity of urokinase and matrix metalloproteinases (MMPs) , that are crucial for cancer growth. (5) (6) (7) Among these catechins, epigallocatechin-3 gallate (EGCG) has the highest antioxidant capacity and is an effective inhibitor of corneal vascularization in vivo. (8) The tumor microenvironment has recently been regarded as a target of cancer chemoprevention because it plays an important role in tumorigenesis and tumor progression. (9) Tumor angiogenesis is one of the key processes within the tumor microenvironment, and controlling this process is a very important strategy for preventing invasive cancers. (10) Many molecules regulating tumor angiogenesis have (VEGF). (11, 12) EGCG has also been shown to inhibit cell proliferation, (13) binding of VEGF to its receptors, (14) phosphorylation of VEGF receptor 2 (VEGFR2), (15) MMP activity, (13) and interleukin-8 production, (16) in normal endothelial cells such as human vascular endothelial cells (HUVECs).
An important concept in tumor angiogenesis is that tumor blood vessels contain endothelial cells that are genetically normal and stable, whereas tumor cells are typically genetically unstable. (17) However, tumor vessels and tumor-associated endothelial cells (TECs) differ from their normal counterparts in many respects. (18) (19) (20) Tumor vessels show structural changes such as fewer pericytes, leakiness. (19, 21) Moreover, some studies have reported that TECs possess molecular characteristics distinct from those of normal endothelial cells (NECs). Endothelial cells derived from human renal cell carcinoma express biological features different from those of NECs. (22) We have reported that endothelial cells in malignant tumors (melanomas and liposarcomas) are cytogenetically abnormal. (23, 24) In addition, TECs showed enhanced F o r R e v i e w -6 -responsiveness to EGF, with alteration of EGF receptor expression. (25) These results suggest that TECs are different from NECs, contrary to the conventional assumption.
We therefore decided to investigate the differential anti-angiogenic effect of EGCG on TECs and NECs.
In the tumor microenvironment, endothelial progenitor cells (EPCs) also play a critical role in tumor angiogenesis. The mobilization of EPCs from the bone marrow into peripheral blood is regulated by tumor-derived cytokines. (26, 27) In response to these cytokines, EPCs can contribute to tumor angiogenesis and the growth of certain tumors. (26, 28, 29) EPCs derived from the bone marrow are thus considered to be an important target for anti-angiogenic therapy. Strategies that block the mobilization of EPCs into circulation might provide a new approach to inhibiting tumor angiogenesis.
(26) However, the effects of EGCG on EPC mobilization have not been investigated. It is of great interest to investigate whether EGCG specifically acts on TECs and EPCs rather than NECs.
To investigate the effects of EGCG on TECs and EPCs, TECs were isolated and cultured from human tumor xenografts in nude mice and EPCs were isolated from nude We also investigated the effect of EGCG on EPC mobilization in VEGF-treated nude mice. In addition, we isolated bone marrow stromal cells (BMSCs) from oral carcinoma-bearing mice and investigated the expression of MMP-9 mRNA in the presence and absence of EGCG in BMSCs to determine whether EGCG affects the expression of MMP-9 in the bone marrow space, which is plays an important role in the mobilization of EPCs into peripheral circulation. (26, 30) Finally, we analyzed the effects of EGCG on in vivo tumor growth.
Materials and Methods

Chemicals.
EGCG Co.) supplemented with 10% FBS.
Antibodies.
The antibodies were purchased: rat anti-mouse CD31 and fluorescein isothiocyanate (FITC)-anti-mouse CD31 (eBioscience, San Diego, CA); FITC-anti-mouse CD133
(eBioscience); FITC-Bandeirea simplicifolia lectin 1-B4 (BS1-B4; Vector Laboratories, Burlingame, CA); FITC-goat anti-rat IgG; phycoerythin (PE)-goat anti-rat IgG (Molecular Probes, Invitrogen, OR); normal rat IgG (BD Pharmingen); PE-anti-mouse VEGFR2 (BD Pharmingen); FITC-Sca-1 (BD Pharmingen).
Isolation of TECs, peripheral blood-derived ECs (EPCs) and NECs.
All animal procedures were performed in compliance with Hokkaido University guidelines, and the protocols were approved by the Institutional Animal Care and Use 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Committee. ECs were isolated as previously described. (23) In brief, TECs were isolated from melanoma (A375SM) and oral carcinoma (HSC-3) xenografts in nude mice aged 8-12 weeks (Sankyo Labo, Tokyo, Japan). NECs were isolated from the dermal tissue as control. ECs were isolated using a magnetic cell sorting system (Miltenyi Biotec, Tokyo, Japan) according to the manufacturer's instructions using FITC-anti-CD31
antibody. CD31-positive cells were sorted and plated onto 1.5% gelatin-coated culture plates and grown in EGM-2 MV (Clonetics, Walkersville, MD) and 15% FBS.
Diphtheria toxin (500 ng/mL; Calbiochem, San Diego, CA) was added to TEC subcultures to kill any remaining human tumor cells (31) and to NECs to ensure technical consistency. The isolated ECs were purified by a second round of purification, using FITC-BS1-B4, and purity was determined by flow cytometry. (23) Peripheral blood-derived ECs were isolated and grown in previously described with modifications. (32) 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 On day 4, non-adherent cells were removed. On day 7, cells were trypsinized and passaged to 6-well tissue culture dishes coated with 1.5% gelatin. Cells were passaged at a 1: 3 ratio until they reached 90% confluence. Peripheral blood-derived ECs were regarded as EPCs since they were Sca-1-positive in culture.
Cell migration assay.
Migration of TECs, NECs, and EPCs was measured by a migration assay using a Boyden chamber as previously described with modifications. (33, 34) 
Western blotting.
ECs were harvested in serum-free medium after16 h and were then treated with EGCG (100 µM) in EBM-2+0.5% FBS for 24 h. Similarly, after starvation for overnight in EBM-2+0.5% FBS, ECs were pretreated with LY294002 (20 µM) for 2hr in EBM-2+0.5%. EGCG was not toxic at these concentrations in these cells. After EGCG treatment, VEGF (10 ng/mL) was added to the cell cultures for 30 min at room temperature. ECs were lysed as described previously with some modification. (25) Total protein was measured using a BCA protein assay kit (Pierce, Rockford, IL). Western blotting was also performed for the detection of the Akt and phosphorylated Akt (P-Akt), as previously described with modifications. (35) After electrotransfer, the PBS or VEGF (300 ng) was injected intraperitoneally into ten nude mice in each group to mobilize EPCs from the bone marrow, as previously described. (36, 37) In each group, EGCG (5 mg/kg) or vehicle was also injected once a day for 2 days. Injection of EGCG into nude mice had no toxic effects. Forty-eight hours after the first injection, peripheral blood (700-1000 µL) was collected under anesthesia in each group (n = 5 for each group) before they were sacrificed. Mononuclear cells were isolated by sucrose gradient centrifugation from peripheral blood as previously described with modifications (38) 
Reverse transcription-PCR (RT-PCR) and quantitative real-time PCR.
Total RNA was isolated from ECs and BMSCs using the RNeasy Micro Kit (Qiagen, Santa Clarita, CA) with RNase-Free DNase Set (Qiagen). RNA was quantified by spectrophotometry. Total RNA (5 µg) was then used for first-strand complementary DNA (cDNA) synthesis in ReverTra-Plus (Toyobo). The cDNA was amplified by polymerase chain reaction (PCR) with primer pairs specific for mouse stromal derived factor-1 (SDF-1), fibroblast activation protein (FAP), α-smooth muscle actin (α-SMA),
and Sca-1. The annealing temperature was 60°C and the reaction proceeded for 30
cycles. PCR products were visualized by ethidium bromide staining and ultraviolet transillumination. NECs were used as a negative control. The primers were as follows:
GAPDH, forward 5′-TCTGACGTGCCGCCTGGAG-3′, reverse 5′-TCGCAGGAGACAACCTGGTC-3′; SDF-1, forward 
Primary culture and characterization of BMSCs.
BMSCs were isolated from the femoral bone marrow of nude mice. The cells were and stem cell marker (Sca-1).
In vivo tumor growth experiments.
Seven-week-old KSN nude mice were purchased from Sankyo Labo and housed in pathogen-free conditions. Melanoma was obtained by s.c injection of A375SM (1×10 6 cells) in the flanks of nude mice as described previously (23) . Animals were randomized into two groups. Controls were injected with 0.05% DMSO and one group was injected with EGCG (20mg/kg) intraperitoneally (n = 5, for each group). The infusion was cooled to room temperature, filtered, and stored at -20°C until use. EGCG was injected every day. Animals were weighed, and tumor growth was monitored for 36 days by measuring two tumor diameters every 3 days with calipers and calculating the tumor volumes with the formula: (the shortest diameter) 2 × (the longest diameter) × 0.5. On 
Statistical Analysis.
Differences between groups were evaluated using the student's t-test, two ways ANOVA test.
Results
TECs and peripheral blood-derived endothelial cells (EPC) expressed Sca-1.
Endothelial cells and peripheral blood-derived endothelial cells (EPC) were characterized by flow cytometry. All ECs, and peripheral blood-derived endothelial cells were positive for BS1-B4, which binds specifically to mouse endothelial cells ( Fig.1a: a-d) . Peripheral blood-derived endothelial cells expressed the stem cell marker Sca-1. Furthermore, Sca-1 was overexpressed also in TECs from both melanoma and oral carcinoma whereas it was expressed at low-level in NECs (Fig.1a: e-h). (Fig.1b) . The cryosections of xenografted-melanoma were processed for immunohistochemistry using FITC-anti-mouse Stem cell antigen-1 (Sca-1) and PEanti-mouse CD31. Representative images demonstrate CD31+ cells (red), Sca-1+ cells (green), and CD31+/Sca-1+ (yellow). Nuclei were stained with DAPI (blue).
CD31+/Sca-1+ cells (yellow) localized in some tumor vessels. These data suggests that
TECs and peripheral blood-derived endothelial cells contain EPC-derived endothelial cells. Since peripheral blood-derived endothelial cells were cultured from PBMCs, we assumed that they can be used to investigate the effects of EGCG on EPCs.
EGCG inhibited the migration of TECs and EPCs.
Since the PI3K-Akt signaling pathway has recently been shown to promote survival of TEC and migration (22, 40) that subsequently lead to angiogenesis, we analyzed the effect of the PI3K inhibitor LY294002 on VEGF-induced migration in ECs and EPCs.
LY294002 (20μM) suppressed the VEGF-induced cell migration of ECs and EPCs.
These results suggest that cell migration of ECs and EPCs is stimulated by VEGF TECs and EPCs toward VEGF, as compared with NECs (*P < 0.05) (Fig. 2) .
EGCG inhibited Akt phosphorylation in TECs.
During angiogenesis, VEGF signaling is mediated by ligand-dependent signaling through the PI3K/Akt pathway. (41) The protein kinase Akt plays a central role in mature endothelial cells. Activation of Akt promotes survival by inhibiting apoptosis (42, 43) and mediates VEGF-induced migration in endothelial cell. (44, 45) Since it was shown that PI3K/Akt pathway is involved in cell migration of ECs and EPC, we analyzed the level of Akt phosphorylation on these cells, using LY294002 or EGCG. Pretreatment with LY294002 (20μM) decreased VEGF-induced Akt activation in TECs not in NECs.
EGCG reduced the levels of phosphorylated Akt stimulated by VEGF in TECs, as well.
( Fig.3a, b) . Specific inhibition of the PI3K/Akt pathway by EGCG in TECs is a possible explanation for the differential effect of EGCG on cell migration between TECs and NECs, as shown in Fig. 2 . 5) . These results suggest that EGCG inhibits the VEGF-induced mobilization of EPCs into circulation. There was no significant difference between the VEGF group and the VEGF + EGCG-treated group.
VEGF receptor 2 (VEGFR2) was upregulated in TECs and EPCs.
EGCG suppressed the expression of MMP-9 in BMSCs from oral carcinoma-bearing mice.
MMP-9 in the bone marrow plays an important role in the mobilization of bone marrow-derived VEGFR-2 + cells into peripheral circulation. (27) In order to test the effects of EGCG on MMP-9 expression in BMSCs, we isolated BMSCs from oral (Fig.6a) . To investigate whether EGCG affects the expression of MMP-9 mRNA in BMSCs, these cells were treated with or without EGCG (25, 50, 100 µM) for 24 h and the expression levels of MMP-9 mRNAs, normalized to GAPDH, were analyzed by real-time PCR.
MMP-9 mRNA expression in BMSC was down-regulated by EGCG. Relative expression level of MMP-9 after 25µM, 50µM and 100µM of EGCG treatment was 0.49, 0.46, and 0.37, respectively (P<0.05) (Fig. 6b) .
EGCG inhibited tumor growth in vivo.
To address the question whether EGCG inhibits tumor growth in vivo, either EGCG or vehicle as a control was administrated intraperitoneally into the mice which bear melanoma xenografted subcutaneously. There was significant difference between EGCG-treated and control tumors (P <0.05) (Fig. 7a) . Drug treatment was well-tolerated without apparent toxicity or body weigh We demonstrate for the first time that EGCG specifically targets TECs and EPCs.
Although we did not identify the molecules responsible for this specificity, the specific The expression of MMP-9 mRNA was significantly down-regulated by EGCG treatment in BMSCs. MMPs play key roles in cancer invasion and metastasis.
Upregulated MMP-9 activity in bone marrow cleaves the membrane-bound stem cell cytokine mKitL expressed by BMSCs to liberate soluble sKitL. The survival activity of sKitL then stimulate the mobilization of bone marrow-derived VEGFR2+cells to peripheral circulation. In MMP-9-/-mice, release of sKitL, hematopoietic cell motility and the mobilization of bone marrow-derived VEGFR2+ cell are impaired. (27) EGCG 3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Ten nude mice in each group were injected intraperitoneally with PBS or a high dose of VEGF (300 ng) to mobilize EPCs from the bone marrow. Next, in each group, EGCG (5 mg/kg) or vehicle was injected once a day for 2 days. Forty-eight hours later, peripheral blood was collected from each mouse in each group (n = 5 for each group) before they were killed. PBMCs were collected and incubated with FITC-anti-mouse CD133 and PE-anti-mouse VEGFR2, and the number of CD133+/VEGFR2+ cells was counted by flow cytometry. Although there was no significant difference between the VEGF group and the VEGF + EGCG group, the low dose of EGCG (5 mg /kg) moderately decreased the number of VEGF-mobilized CD133+/VEGFR2+ cells that migrated into peripheral circulation. µM). Expression levels of MMP-9 mRNAs were normalized to GAPDH. EGCG significantly reduced MMP-9 mRNA levels in BMSCs. The experiment was performed three times with similar results (*P< 0.05 versus 0µM) . 3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 
